Quantcast

Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials

September 1, 2009

SCHAUMBURG, Ill., Sept. 1 /PRNewswire/ — Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of adenosine injection, USP, an antiarrhythmic drug used to treat paroxysmal supraventricular tachycardia. Sagent will offer this latex-free, preservative-free adenosine product in 6 mg per 2 mL single-dose glass vials for intravenous use.

“This launch expands upon the full line of prefilled adenosine syringes we introduced in 2007, providing caregivers an array of adenosine delivery options in cardiac care settings,” said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. “Our 2 mL adenosine vial is the second product introduced from our collaboration with Strides Arcolab.”

Sagent and Strides Arcolab are jointly developing, supplying and marketing more than 25 injectable products for the U.S. market.

About Adenosine Injection, USP

Adenosine Injection, USP, is the generic equivalent of Astellas Pharma U.S., Inc.’s Adenocard(R), an antiarrhythmic commonly used in the treatment of paroxysmal supraventricular tachycardia, a rhythm disturbance of the heart, in critical care situations. Adenosine works by slowing the electrical conduction in the heart, slowing heart rate of normalizing heart rhythm.

Adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.

SOURCE Sagent Pharmaceuticals, Inc.


Source: newswire



comments powered by Disqus